| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2019 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 5 | NIH | 7/27/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 5 | NIH | 3/5/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 5 | NIH | 4/24/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $602,843 ) |
| | 2019 | 2019 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 5 | NIH | 7/31/2019 | $602,843 |
|
| Issue Date FY: 2018 ( Subtotal = $1,123,236 ) |
| | 2018 | 2018 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 4 | NIH | 8/7/2018 | $1,123,236 |
|
| Issue Date FY: 2017 ( Subtotal = $1,758,066 ) |
| | 2017 | 2017 | ORYGEN | 35 POPLAR RD | PARKVILLE | VIC | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 3 | NIH | 8/24/2017 | $1,758,066 |
|
| Issue Date FY: 2016 ( Subtotal = $1,616,896 ) |
| | 2016 | 2016 | ORYGEN | 35 POPLAR ROAD | PARKVILLE 3052 | | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 2 | NIH | 7/23/2016 | $1,616,896 |
|
| Issue Date FY: 2015 ( Subtotal = $902,037 ) |
| | 2015 | 2015 | ORYGEN | 35 POPLAR ROAD | PARKVILLE 3052 | | 3052 | | AUS | U01MH105258 | Building the Evidence Base for Adaptive Treatment Sequences in Clinical High Risk | 000 | 1 | NIH | 7/23/2015 | $902,037 |
|
|
